electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
April 06, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a...
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
April 04, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the...
electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023 16:05 ET
|
electroCore, Inc.
Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J.,...
National Headache Foundation Makes WorkMigraine Program Resources Free to the Public
January 05, 2023 15:18 ET
|
National Headache Foundation
Chicago, Illinois, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The National Headache Foundation (NHF) announced it is now making available free to the public its proven WorkMigraine program to help employers...
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
September 29, 2022 07:28 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Neuromodulation Devices Market to Hit $14.16 Billion by 2030, Growing at a CAGR of 10.29%
September 05, 2022 08:40 ET
|
STRATEGIC MARKET RESEARCH LLP
New York, USA, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The Worldwide Neuromodulation Devices Market value was USD 6.10 Billion in 2021 and will reach USD 14.16 Billion in 2030 with a 10.29% CAGR....
Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor
September 01, 2022 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Global Neuromodulation Market to Reach $4.3 Bn Globally, by 2030, at 6.2% CAGR: Says AMR
June 15, 2022 07:47 ET
|
Allied Market Research
Portland, OR, June 15, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Neuromodulation Market was estimated at $2.48 billion in 2020, and is...
New West Dental Ceramics Launches Sleep and Migraine Appliances, New Blog
May 19, 2022 11:00 ET
|
New West Dental Ceramics
LAKE HAVASU CITY, Ariz., May 19, 2022 (GLOBE NEWSWIRE) -- New West Dental Ceramics has always been dedicated to providing superior dental services to its customers. This quarter, the dental lab has...
Migraine Market Size, Growth, Trends [2022-2029] | Global Industry Share, Key Players, Demand, Type & Application, Market Dynamics, Sales, Revenue, Price and Gross Margin, Supply Chain and Forecast Research | Market Reports World
April 25, 2022 05:17 ET
|
Market Reports World
Pune, April 25, 2022 (GLOBE NEWSWIRE) -- The global Migraine Market 2022 research report provides an in-depth analysis of market size, share, growth, trends and forecast. The Migraine Market...